S89704 |
GW590735 |
源葉(MedMol) | 98% |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.09 ml | 10.45 ml | 20.9 ml |
5 mM | 0.418 ml | 2.09 ml | 4.18 ml |
10 mM | 0.209 ml | 1.045 ml | 2.09 ml |
50 mM | 0.042 ml | 0.209 ml | 0.418 ml |
- 產(chǎn)品描述: GW 590735 is a potent and selective PPARα agonist. GW 590735 showsEC50=4 nM on PPARα and at least 500-fold selectivity versus PPARδ and PPARγ. GW 590735 can be used for the research of dyslipidemia
- 靶點(diǎn): PPAR
- 體內(nèi)研究:
GW 590735 (0.5-5 mg/kg; orally twice a day for 5 days) is able to lower LDLc and triglycerides (TG) and increase HDL cholesterol in the Apo-A-I-transgenic mouse model (male C57BL/6 mice transgenic for human ApoA-I).
GW 590735 (intravenous administration; 2.7 mg/kg; rat) treatment shows Cl, Vd, T1/2, and F% are 5 mL/min/kg, 1 L/kg, 2.4 hours and 47%, respectively.
GW 590735 (intravenous administration; 2 mg/kg; dog) treatment shows Cl, Vd, T1/2, and F% are 13 mL/min/kg, 2.8 L/kg, 2.6 hours and 85%, respectively.
- 參考文獻(xiàn):
1. Sierra ML, et al. Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents. J Med Chem. 2007;50(4):685-695.
- 溶解性: Soluble in DMSO
- 保存條件: -20°C
- 配置溶液濃度參考:
1mg 5mg 10mg 1 mM 2.09 ml 10.45 ml 20.9 ml 5 mM 0.418 ml 2.09 ml 4.18 ml 10 mM 0.209 ml 1.045 ml 2.09 ml 50 mM 0.042 ml 0.209 ml 0.418 ml
- 注意:部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。
輸入產(chǎn)品批號:
本計(jì)算器可幫助您計(jì)算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系,公式為:
質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)